buprenorfine sandoz weekly 5 µg/h transderm. patch sachet
sandoz sa-nv - buprenorphine 5 mg - transdermal patch - 5 µg/h - buprenorphine 5 mg - buprenorphine
buprenorfine sandoz weekly 10 µg/h transderm. patch sachet
sandoz sa-nv - buprenorphine 10 mg - transdermal patch - 10 µg/h - buprenorphine 10 mg - buprenorphine
buprenorfine sandoz weekly 15 µg/h transderm. patch sachet
sandoz sa-nv - buprenorphine 15 mg - transdermal patch - 15 µg/h - buprenorphine 15 mg - buprenorphine
buprenorfine sandoz weekly 20 µg/h transderm. patch sachet
sandoz sa-nv - buprenorphine 20 mg - transdermal patch - 20 µg/h - buprenorphine 20 mg - buprenorphine
doloforte denk tablets film-coated
denk pharma gmbh & co. kg - tramadol (tramadol hydrochloride), paracetamol - tablets film-coated - 37,5mg+ 325mg
selincro
h. lundbeck a/s - nalmefene hydrochloride dihydrate - alcohol-related disorders - drugs used in alcohol dependence - selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking-risk level (see section 5.1), without physical withdrawal symptoms and who do not require immediate detoxification.selincro should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption.selincro should be initiated only in patients who continue to have a high drinking-risk level two weeks after initial assessment.
addictex 0.4mg sublingual tablets
actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - buprenorphine - sublingual tablet - buprenorphine 0.4 mg - other nervous system drugs
addictex 2mg sublingual tablets
actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - buprenorphine - sublingual tablet - buprenorphine 2 mg - other nervous system drugs
addictex 8mg sublingual tablets
actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - buprenorphine - sublingual tablet - buprenorphine 8 mg - other nervous system drugs
efavirenz/emtricitabine/tenofovir disoproxil zentiva
zentiva k.s. - efavirenz, emtricitabine, tenofovir disoproxil, phosphate - hiv infections - antivirals for systemic use, - efavirenz/emtricitabine/tenofovir disoproxil zentiva is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. it is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults aged 18 years and over with virologic suppression to hiv-1 rna levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in efavirenz/emtricitabine/tenofovir disoproxil zentiva prior to initiation of their first antiretroviral treatment regimen., the demonstration of the benefit of the combination efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavir